Literature DB >> 20454816

Very low levels of vitamin D in systemic sclerosis patients.

Paola Caramaschi1, Alessandra Dalla Gassa, Orazio Ruzzenente, Alessandro Volpe, Viviana Ravagnani, Ilaria Tinazzi, Giovanni Barausse, Lisa M Bambara, Domenico Biasi.   

Abstract

Vitamin D displays many extraosseous immunomodulatory effects. The aim of the study was to evaluate the level of vitamin D in patients with systemic sclerosis (SSc) and to analyze the associations between the concentration of the vitamin and clinical manifestations. In March-April 2009, 65 consecutive SSc patients underwent evaluation of vitamin D concentrations by the LIAISON immunoassay (normal 30-100 ng/ml). Serum levels between 10 and 30 ng/ml were classified as vitamin D insufficiency, while concentrations <10 ng/ml as vitamin D deficiency. None of the patients were receiving vitamin D supplementation at the time of or during the year prior to study entry. The mean level of vitamin D was 15.8 ± 9.1 ng/ml. Only three cases showed normal values; vitamin D insufficiency and deficiency were found in 43 and 19 cases, respectively. Patients with vitamin D deficiency showed longer disease duration (13.1 ± 6.8 versus 9.4 ± 5.5 years, P = 0.026), lower diffusing lung capacity for carbon monoxide (63.7 ± 12.4 versus 76.4 ± 20.2, P = 0.014), higher estimated pulmonary artery pressure (28.9 ± 9.9 versus 22.8 ± 10.4, P = 0.037) and higher values of ESR (40 ± 25 versus 23 ± 13 mm/h, P = 0.001) and of CRP (7 ± 7 and 4 ± 2 mg/l, P = 0.004) in comparison with patients with vitamin D insufficiency; moreover, late nailfold videocapillaroscopic pattern was more frequently found (52.6% versus 18.6%, P = 0.013). None of the patients showed evidence of overt mal-absorption. Low levels of vitamin D are very frequent in patients with SSc. Intestinal involvement is not likely the cause of vitamin D deficit; other factors such as skin hyperpigmentation and reduced sun exposition for psychological and social reasons may be implicated. Patients with vitamin D deficiency showed more severe disease in comparison with patients with vitamin D insufficiency, above all concerning lung involvement. Further trials are awaited to determine whether vitamin D could represent a modifiable factor able to interfere with SSc evolution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454816     DOI: 10.1007/s10067-010-1478-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

1.  Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations.

Authors:  J W Morgan; N Kouttab; D Ford; A L Maizel
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

2.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis.

Authors:  Brigham C Willis; Janice M Liebler; Katherine Luby-Phelps; Andrew G Nicholson; Edward D Crandall; Roland M du Bois; Zea Borok
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

3.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population.

Authors:  C Bryan; Y Howard; P Brennan; C Black; A Silman
Journal:  Br J Rheumatol       Date:  1996-11

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells.

Authors:  Allan M Ramirez; Cherry Wongtrakool; Teresa Welch; Andreas Steinmeyer; Ulrich Zügel; Jesse Roman
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-17       Impact factor: 4.292

6.  Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors.

Authors:  G Isaia; R Giorgino; G B Rini; M Bevilacqua; D Maugeri; S Adami
Journal:  Osteoporos Int       Date:  2003-07-11       Impact factor: 4.507

7.  Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.

Authors:  Hedi Orbach; Gisele Zandman-Goddard; Howard Amital; Vivian Barak; Zoltan Szekanecz; Gabriella Szucs; Katalin Danko; Endre Nagy; Tunde Csepany; Jozelio F Carvalho; Andrea Doria; Yehuda Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2007-08       Impact factor: 5.691

8.  Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis.

Authors:  Yolanda Braun-Moscovici; Daniel E Furst; Doron Markovits; Alexander Rozin; Philip J Clements; Abraham Menahem Nahir; Alexandra Balbir-Gurman
Journal:  J Rheumatol       Date:  2008-10-01       Impact factor: 4.666

9.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

Review 10.  The complex role of vitamin D in autoimmune diseases.

Authors:  P Szodoray; B Nakken; J Gaal; R Jonsson; A Szegedi; E Zold; G Szegedi; J G Brun; R Gesztelyi; M Zeher; E Bodolay
Journal:  Scand J Immunol       Date:  2008-05-29       Impact factor: 3.487

View more
  35 in total

Review 1.  Does vitamin D affect risk of developing autoimmune disease?: a systematic review.

Authors:  Martin A Kriegel; JoAnn E Manson; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2010-11-02       Impact factor: 5.532

2.  Vitamin D in systemic sclerosis.

Authors:  Laura Belloli; Nicola Ughi; Bianca Marasini
Journal:  Clin Rheumatol       Date:  2010-09-28       Impact factor: 2.980

3.  Vitamin D and autoimmune rheumatic diseases.

Authors:  Paola Caramaschi; Alessandra Dalla Gassa; Orazio Ruzzenente; Alessandro Volpe; Viviana Ravagnani; Ilaria Tinazzi; Giovanni Barausse; Lisa M Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2011-01-18       Impact factor: 2.980

4.  Seasonal variations in serum levels of 25-hydroxyvitamin D in patients with systemic sclerosis.

Authors:  Bruno Seriolo; Luigi Molfetta; Maurizio Cutolo
Journal:  Clin Rheumatol       Date:  2011-01-15       Impact factor: 2.980

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

6.  Vitamin D deficiency in systemic sclerosis: a possible role of subclinical liver fibrosis? Retrospective analysis from an Italian cohort.

Authors:  Francesco Ursini; Salvatore D'Angelo; Angela Padula; Pietro Leccese; Giuseppina Abignano; Gianna Angela Mennillo; Giorgio Ammerata; Giovambattista De Sarro; Ignazio Olivieri
Journal:  Clin Rheumatol       Date:  2017-06-03       Impact factor: 2.980

7.  Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature.

Authors:  Dilia Giuggioli; M Colaci; G Cassone; P Fallahi; F Lumetti; A Spinella; F Campomori; A Manfredi; C U Manzini; A Antonelli; C Ferri
Journal:  Clin Rheumatol       Date:  2017-01-09       Impact factor: 2.980

8.  Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Fahd Wafki; Fatima Znat; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

Review 9.  Vitamin D Deficiency and Rheumatoid Arthritis.

Authors:  Larissa Lumi Watanabe Ishikawa; Priscila Maria Colavite; Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Thais Graziela Donegá França; Sofia Fernanda Gonçalves Zorzella-Pezavento; Fernanda Chiuso-Minicucci; Larissa Doddi Marcolino; Marcimara Penitenti; Maura Rosane Valerio Ikoma; Alexandrina Sartori
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 10.  The role of vitamin D supplementation in patients with rheumatic diseases.

Authors:  Bo Abrahamsen; Nicholas C Harvey
Journal:  Nat Rev Rheumatol       Date:  2013-05-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.